Pipisoxole Hydrochloride

Pipoxolan Hydrochloride is an anti-spasmodic agent primarily targeting smooth muscle relaxation in the digestive, urinary, and gynecological systems. Beyond its spasmolytic activity, Pipoxolan Hydrochloride induces apoptosis and increases intracellular reactive oxygen species (ROS) while simultaneously down-regulating the phosphorylation of JNK and p38 pathways, affecting MMP-2 and MMP-9 activity. Pipoxolan Hydrochloride exhibits anticancer activity against leukemia, oral squamous cell carcinoma, and lung adenocarcinoma. Pipoxolan Hydrochloride has been developed withhundred-kilogram scale production capacity and large-scale production process, achieving pharmaceutical-grade quality. The compound is supplied as a crystalline solid with a melting point of 207–209 °C, is soluble in water, and is stable to mild attack by acids or bases. In quality control contexts, Pipoxolan Hydrochloride serves as a reference standard for analytical method development and quality control applications.

Product Parameters

---

Parameter	Specification
Product Name	Pipoxolan Hydrochloride (Pipisoxole Hydrochloride)
CAS Number	18174-58-8
Molecular Formula	C₂₂H₂₆ClNO₃
Molecular Weight	387.90 g/mol
Melting Point	207–209 °C

Application

---

Pipocaridine hydrochloride is a novel type of surgical adjuvant medication (commonly referred to as an muscle relaxant). When used clinically, it induces muscle relaxation under relatively shallow anesthesia, thereby eliminating the need for deep general anesthesia to achieve adequate muscle relaxation for surgical procedures.

 

Why Cosperpharm?

---

When your anti-spasmodic API manufacturing or pharmaceutical research requires a reliable source of Pipoxolan Hydrochloride, Cosperpharm delivers with the analytical rigor, documentation depth, and supply flexibility that pharmaceutical customers demand.

 

Quality begins with the molecule. The dioxolanone core and piperidine moiety of Pipoxolan Hydrochloride are essential for its anti-spasmodic and anticancer activities—any impurity compromises therapeutic efficacy. Our analytical release protocol for Pipoxolan Hydrochloride includes HPLC purity verification, melting point verification (207–209 °C), residual solvent analysis, and identity confirmation—because your final API's activity depends on the quality of this compound.

 

Documentation that supports regulatory submission. Every shipment of Pipoxolan Hydrochloride includes a Certificate of Analysis (COA) with batch-specific purity data, chromatographic traceability, and residual solvent data. DMF-ready documentation, stability summaries, and custom quality agreements are available upon request.

 

Flexible supply across all development stages. Cosperpharm supplies Pipoxolan Hydrochloride across the full range of applications—from gram-scale R&D quantities for medicinal chemistry and pharmacological research, to kilogram-scale batches for pilot production, to multi-kilogram commercial manufacturing. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.

 

Technical support for the full synthetic cascade. Our process chemistry team can advise on the synthesis of Pipoxolan Hydrochloride, including dioxolanone formation, piperidine substitution, and hydrochloride salt formation, as well as purification strategies for removing process-related impurities.

 

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and analytical laboratories worldwide, with full customs documentation included. Volume discounts apply at kilogram scales.

 

Product Quality Assurance

---

Cosperpharm has established a comprehensive quality assurance system for Pipoxolan Hydrochloride that meets the rigorous expectations of pharmaceutical API manufacturing and analytical reference standard applications:

 

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity (≥98% with full chromatographic traceability), melting point verification (207–209 °C), residual solvent analysis, water content determination, and identity confirmation by NMR and MS.

 

Full batch traceability with retention samples. From raw material procurement through each synthetic step—dioxolanone formation, piperidine substitution, salt formation, purification, and final packaging—every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

 

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. Cosperpharm provides DMF-ready documentation packages and custom quality agreements upon request.

 

Customer-initiated quality audits. Qualified customers are welcome to audit Cosperpharm's manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit.

 

Contact Us

---

Looking for Pipoxolan Hydrochloride for your anti-spasmodic API manufacturing, anticancer research, or analytical reference standard needs? Cosperpharm is here to support your program.